BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants (Basel) 2021;10:270. [PMID: 33578702 DOI: 10.3390/antiox10020270] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 27.5] [Reference Citation Analysis]
Number Citing Articles
1 Koshino A, Oshima M, Arnott C, Fletcher RA, Bakris GL, Jardine M, Mahaffey KW, Perkovic V, Pollock C, Heerspink HJL, Neuen BL. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab 2023. [PMID: 36655422 DOI: 10.1111/dom.14978] [Reference Citation Analysis]
2 Rojano A, Sena E, Manzano-Nuñez R, Pericàs JM, Ciudin A. NAFLD as the metabolic hallmark of obesity. Intern Emerg Med 2023;18:31-41. [PMID: 36357606 DOI: 10.1007/s11739-022-03139-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chun HS, Lee M, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee YH, Kim JH, Kim SU. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int 2022. [PMID: 36585250 DOI: 10.1111/liv.15508] [Reference Citation Analysis]
4 Salvatore T, Galiero R, Caturano A, Rinaldi L, Criscuolo L, Di Martino A, Albanese G, Vetrano E, Catalini C, Sardu C, Docimo G, Marfella R, Sasso FC. Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes. Int J Mol Sci 2022;24. [PMID: 36614099 DOI: 10.3390/ijms24010658] [Reference Citation Analysis]
5 Shea S, Lionis C, Atkinson L, Kite C, Lagojda L, Chaggar SS, Kyrou I, Randeva HS. Support Needs and Coping Strategies in Non-Alcoholic Fatty Liver Disease (NAFLD): A Multidisciplinary Approach to Potential Unmet Challenges beyond Pharmacological Treatment. Livers 2022;3:1-20. [DOI: 10.3390/livers3010001] [Reference Citation Analysis]
6 Gao N, Deng J, Wang J, Zhou Z, Yao C, Zhou M, Xing X, Wang Q, Lu X, Shi H. The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1038475] [Reference Citation Analysis]
7 Lavallee CM, Bruno A, Ma C, Raman M. The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review. Nutrients 2022;14:4655. [DOI: 10.3390/nu14214655] [Reference Citation Analysis]
8 Jiang Y, Cao H, Chen X, Yu G, Song C, Duan H, Tian F, Wan H, Shen J. Associations of serum folate and vitamin C levels with metabolic dysfunction-associated fatty liver disease in US adults: A nationwide cross-sectional study. Front Public Health 2022;10:1022928. [PMID: 36388270 DOI: 10.3389/fpubh.2022.1022928] [Reference Citation Analysis]
9 Cao C, Zhang X, Yuan J, Zan Y, Zhang X, Xue C, Wang Y, Zheng X. Nonlinear relationship between aspartate aminotransferase to alanine aminotransferase ratio and the risk of prediabetes: A retrospective study based on chinese adults. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1041616] [Reference Citation Analysis]
10 Alemayehu HB, Tegegn MT, Tilahun MM. Prevalence and associated factors of visual impairment among adult diabetic patients visiting Adare General Hospital, Hawassa, South Ethiopia, 2022. PLoS One 2022;17:e0276194. [PMID: 36227943 DOI: 10.1371/journal.pone.0276194] [Reference Citation Analysis]
11 Efrem IC, Moța M, Vladu IM, Mitrea A, Clenciu D, Timofticiuc DCP, Diaconu ID, Turcu A, Crișan AE, Geormăneanu C, Glodeanu AD, Mahler B, Tudor MS, Amzolini AM, Micu SE, Barău Abu Alhija A, Mită A, Filip MM, Forțofoiu M. A Study of Biomarkers Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes. Diagnostics (Basel) 2022;12:2426. [PMID: 36292115 DOI: 10.3390/diagnostics12102426] [Reference Citation Analysis]
12 Ma W, Wu W, Wen W, Xu F, Han D, Lyu J, Huang Y. Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. Ther Adv Chronic Dis 2022;13:20406223221122478. [PMID: 36159632 DOI: 10.1177/20406223221122478] [Reference Citation Analysis]
13 Zhu Z, Yang N, Fu H, Yuan G, Chen Y, Du T, Zhou X. Associations of lipid parameters with non-alcoholic fatty liver disease in type 2 diabetic patients according to obesity status and metabolic goal achievement. Front Endocrinol 2022;13:1002099. [DOI: 10.3389/fendo.2022.1002099] [Reference Citation Analysis]
14 Chen M, Wu C, Zhang J, Zhang H, Sun Y, Tian S, Han J. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. Front Endocrinol 2022;13:996228. [DOI: 10.3389/fendo.2022.996228] [Reference Citation Analysis]
15 Salvatore T, Galiero R, Caturano A, Vetrano E, Loffredo G, Rinaldi L, Catalini C, Gjeloshi K, Albanese G, Di Martino A, Docimo G, Sardu C, Marfella R, Sasso FC. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines 2022;10:2274. [DOI: 10.3390/biomedicines10092274] [Reference Citation Analysis]
16 Asaturyan HA, Basty N, Thanaj M, Whitcher B, Thomas EL, Bell JD. Improving the accuracy of fatty liver index to reflect liver fat content with predictive regression modelling. PLoS ONE 2022;17:e0273171. [DOI: 10.1371/journal.pone.0273171] [Reference Citation Analysis]
17 De Nucci S, Castellana F, Zupo R, Lampignano L, Di Chito M, Rinaldi R, Giannuzzi V, Cozzolongo R, Piazzolla G, Giannelli G, Sardone R, De Pergola G. Associations between serum biomarkers and non-alcoholic liver disease: Results of a clinical study of Mediterranean patients with obesity. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.1002669] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Mare R, Sporea I. Gastrointestinal and Liver Complications in Patients with Diabetes Mellitus-A Review of the Literature. J Clin Med 2022;11:5223. [PMID: 36079153 DOI: 10.3390/jcm11175223] [Reference Citation Analysis]
19 Tsankof A, Neokosmidis G, Koureta E, Veneti S, Cholongitas E, Tziomalos K. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease? Front Endocrinol 2022;13:984041. [DOI: 10.3389/fendo.2022.984041] [Reference Citation Analysis]
20 Zhou X, Lin X, Chen J, Pu J, Wu W, Wu Z, Lin H, Huang K, Zhang L, Dai Y, Ni Y, Dong G, Fu J. Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity. Front Endocrinol 2022;13:986841. [DOI: 10.3389/fendo.2022.986841] [Reference Citation Analysis]
21 Diaconu C, Guja C. Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies. JCM 2022;11:5144. [DOI: 10.3390/jcm11175144] [Reference Citation Analysis]
22 Ismaiel A, Ciobanu OS, Ismaiel M, Leucuta D, Popa S, David L, Ensar D, Al Srouji N, Dumitrascu DL. Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Biomedicines 2022;10:2101. [DOI: 10.3390/biomedicines10092101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Song Z, Luo W, Huang B, Cao Y, Jiang R. A new predictive model for the concurrent risk of diabetic retinopathy in type 2 diabetes patients and the effect of metformin on amino acids. Front Endocrinol 2022;13:985776. [DOI: 10.3389/fendo.2022.985776] [Reference Citation Analysis]
24 Zeng C, Chen M. Progress in Nonalcoholic Fatty Liver Disease: SIRT Family Regulates Mitochondrial Biogenesis. Biomolecules 2022;12:1079. [PMID: 36008973 DOI: 10.3390/biom12081079] [Reference Citation Analysis]
25 Xiao Y, Liu Y, Zhao L, Zhou Y. Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2022. [PMID: 35925752 DOI: 10.1089/met.2022.0014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Doustmohammadian A, Nezhadisalami A, Safarnezhad Tameshke F, Motamed N, Maadi M, Farahmand M, Sohrabi M, Clark CCT, Ajdarkosh H, Faraji AH, Nikkhah M, Sobhrakhshankhah E, Ebrahimi R, Zamani F. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Front Med 2022;9. [DOI: 10.3389/fmed.2022.937554] [Reference Citation Analysis]
27 Riemann A, Blaschke M, Jauho-ghadimi A, Siggelkow H, Gollisch KSC. Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome. JCM 2022;11:4294. [DOI: 10.3390/jcm11154294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Martínez-Urbistondo D, San Cristóbal R, Villares P, Martínez-González MÁ, Babio N, Corella D, Del Val JL, Ordovás JM, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem JL, Bueno-Cavanillas A, Tur JA, Marcos A, Pintó X, Delgado-Rodríguez M, Matía-Martín P, Vidal J, Vázquez C, Ros E, Bullón Vela MV, Palau A, Masagué M, Abete I, Moreno-Rodríguez A, Candela-García I, Konieczna J, García-Ríos A, Juárez OL, Martín P, Goday A, Zulet MÁ, Vaquero-Luna J, Orea MDCS, Megías I, Baltasar E, Martínez JA, Daimiel L. Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort. Front Endocrinol (Lausanne) 2022;13:868795. [PMID: 35846291 DOI: 10.3389/fendo.2022.868795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Xie M, Zhang X, Wu Y, Sun J, Yu W, Cui P. Study on the Correlation Between Biliary Tract and Intestinal Flora and the Formation of Gallstones.. [DOI: 10.1101/2022.06.28.22277035] [Reference Citation Analysis]
30 Nurcahyanti ADR, Cokro F, Wulanjati MP, Mahmoud MF, Wink M, Sobeh M. Curcuminoids for Metabolic Syndrome: Meta-Analysis Evidences Toward Personalized Prevention and Treatment Management. Front Nutr 2022;9:891339. [PMID: 35757255 DOI: 10.3389/fnut.2022.891339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Sun J, Zhang D, Li Y. Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease. Front Physiol 2022;13:909518. [DOI: 10.3389/fphys.2022.909518] [Reference Citation Analysis]
32 George ES, Georgousopoulou EN, Mellor DD, Chrysohoou C, Pitsavos C, Panagiotakos DB. Exploring the Path of Mediterranean Diet, Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation towards 10-Year Cardiovascular Disease (CVD) Risk: The ATTICA Study 10-Year Follow-Up (2002-2012). Nutrients 2022;14:2367. [PMID: 35745097 DOI: 10.3390/nu14122367] [Reference Citation Analysis]
33 Guo Y, Yang J, Ma R, Zhang X, Guo H, He J, Wang X, Cao B, Maimaitijiang R, Li Y, Peng X, Zhang S, Guo S. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. Nutrients 2022;14:2361. [PMID: 35745091 DOI: 10.3390/nu14122361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tagi VM, Mainieri F, Chiarelli F. Hypertension in Patients with Insulin Resistance: Etiopathogenesis and Management in Children. IJMS 2022;23:5814. [DOI: 10.3390/ijms23105814] [Reference Citation Analysis]
35 Guagnano MT, D'ardes D, Ilaria R, Santilli F, Schiavone C, Bucci M, Cipollone F. Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. JCM 2022;11:2759. [DOI: 10.3390/jcm11102759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhang J, Zhang J, Tao Z. Effect of Comorbid Diabetes on Clinical Characteristics of COVID-19 Patients Infected by the Wild-Type or Delta Variant of SARS-CoV-2. Front Endocrinol 2022;13:861443. [DOI: 10.3389/fendo.2022.861443] [Reference Citation Analysis]
37 Bashir A, Duseja A, De A, Mehta M, Tiwari P. Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena. Liver Research 2022. [DOI: 10.1016/j.livres.2022.05.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
38 Gabriel-medina P, Ferrer-costa R, Rodriguez-frias F, Ciudin A, Augustin S, Rivera-esteban J, Pericàs JM, Selva DM. Influence of Type 2 Diabetes in the Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms in NASH Advanced Liver Fibrosis. Biomedicines 2022;10:1015. [DOI: 10.3390/biomedicines10051015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Boonchai P, Kositamongkol C, Jitrukthai S, Phothirat S, Mepramoon E, Nimitpunya P, Srivanichakorn W, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Tinmanee R, Sayabovorn N, Charatcharoenwitthaya P, Phisalprapa P. Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome. J Clin Med 2022;11:2445. [PMID: 35566571 DOI: 10.3390/jcm11092445] [Reference Citation Analysis]
40 Zhao P, Yan J, Pan B, Liu J, Fu S, Cheng J, Wang L, Jing G, Li Q. Association Between the Risk of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. Diabetes Metab Syndr Obes 2022;15:1141-51. [PMID: 35444436 DOI: 10.2147/DMSO.S356497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Schmid A, Arians M, Karrasch T, Pons-Kühnemann J, Schäffler A, Roderfeld M, Roeb E. Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. J Clin Med 2022;11:1756. [PMID: 35407364 DOI: 10.3390/jcm11071756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
43 Jiang Z, Zhu J, Shen H, Zhao S, Tang Y, Tang S, Liu X, Jiang T. A High Triglyceride-Glucose Index Value Is Associated With an Increased Risk of Carotid Plaque Burden in Subjects With Prediabetes and New-Onset Type 2 Diabetes: A Real-World Study. Front Cardiovasc Med 2022;9:832491. [DOI: 10.3389/fcvm.2022.832491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Song K, Park G, Lee HS, Lee M, Lee HI, Ahn J, Lee E, Choi HS, Suh J, Kwon A, Kim H, Chae HW. Trends in Prediabetes and Non-Alcoholic Fatty Liver Disease Associated with Abdominal Obesity among Korean Children and Adolescents: Based on the Korea National Health and Nutrition Examination Survey between 2009 and 2018. Biomedicines 2022;10:584. [DOI: 10.3390/biomedicines10030584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Kosmalski M, Ziółkowska S, Czarny P, Szemraj J, Pietras T. The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. J Clin Med 2022;11:1375. [PMID: 35268466 DOI: 10.3390/jcm11051375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Yang C, He Q, Chen Z, Qin J, Lei F, Liu Y, Liu W, Chen M, Sun T, Zhu Q, Wu Y, Zhuo M, Cai J, Mao W, Li H. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. Front Endocrinol 2022;13:821689. [DOI: 10.3389/fendo.2022.821689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
47 Xing Y, Chen J, Liu J, Song G, Ma H. Relationship Between Serum Uric Acid-to-Creatinine Ratio and the Risk of Metabolic-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes 2022;15:257-67. [PMID: 35140486 DOI: 10.2147/DMSO.S350468] [Reference Citation Analysis]
48 Craciun C, Neag M, Catinean A, Mitre A, Rusu A, Bala C, Roman G, Buzoianu A, Muntean D, Craciun A. The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus. Biomedicines 2022;10:308. [DOI: 10.3390/biomedicines10020308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
49 Rajewski P, Zarębska-Michaluk D, Janczewska E, Gietka A, Mazur W, Tudrujek-Zdunek M, Tomasiewicz K, Belica-Wdowik T, Baka-Ćwierz B, Dybowska D, Halota W, Lorenc B, Sitko M, Garlicki A, Berak H, Horban A, Orłowska I, Simon K, Socha Ł, Wawrzynowicz-Syczewska M, Jaroszewicz J, Deroń Z, Czauż-Andrzejuk A, Citko J, Krygier R, Piekarska A, Laurans Ł, Dobracki W, Białkowska J, Tronina O, Wietlicka-Piszcz M, Pawłowska M, Flisiak R. HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study. J Clin Med 2022;11:379. [PMID: 35054072 DOI: 10.3390/jcm11020379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Forlano R, Mullish BH, Roberts LA, Thursz MR, Manousou P. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:662. [PMID: 35054847 DOI: 10.3390/ijms23020662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
51 Santos JPMD, Maio MC, Lemes MA, Laurindo LF, Haber JFDS, Bechara MD, Prado PSD Jr, Rauen EC, Costa F, Pereira BCA, Flato UAP, Goulart RA, Chagas EFB, Barbalho SM. Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. Int J Mol Sci 2022;23:498. [PMID: 35008925 DOI: 10.3390/ijms23010498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
52 Qian L, Tian S, Jiang S, Tang Y, Han T. DHA-enriched phosphatidylcholine from Clupea harengus roes regulates the gut–liver axis to ameliorate high-fat diet-induced non-alcoholic fatty liver disease. Food Funct 2022. [DOI: 10.1039/d2fo02672d] [Reference Citation Analysis]
53 Meritsi A, Manesis E, Koussis P, Rapti S, Latsou D, Tsitsopoulos E, Moshoyianni H, Manolakopoulos S, Pektasides D, Thanopoulou A. PNPLA3 rs 738409 and Other Nongenetic Factors Associated with Hepatic Steatosis Estimated by Magnetic Resonance Imaging Proton Density Fat Fraction in Adult Greek Subjects with Type 2 Diabetes Mellitus. Metab Syndr Relat Disord 2021. [PMID: 34962148 DOI: 10.1089/met.2021.0098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients 2021;14:103. [PMID: 35010976 DOI: 10.3390/nu14010103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
55 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Yan JX, Pan BJ, Zhao PP, Wang LT, Liu JF, Fu SB. Serum ferritin is correlated with non-alcoholic fatty liver disease in middle-aged and older patients with type 2 diabetes. Endocr Connect 2021;10:1560-9. [PMID: 34738917 DOI: 10.1530/EC-21-0367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Shea S, Lionis C, Kite C, Atkinson L, Chaggar SS, Randeva HS, Kyrou I. Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress. Biomedicines 2021;9:1697. [PMID: 34829926 DOI: 10.3390/biomedicines9111697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
58 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
59 Alzahrani Q, Pinto L. Epistemological Assumption: Understanding Protein Polysaccharide Complexes in Improving Diabetes Treatment. NRFHH 2021;1:110-117. [DOI: 10.53365/nrfhh/142486] [Reference Citation Analysis]
60 Hsu WH, Tseng CW, Huang YT, Liang CC, Lee MY, Chen SC. Common Risk Factors in Relatives and Spouses of Patients with Type 2 Diabetes in Developing Prediabetes. Healthcare (Basel) 2021;9:1010. [PMID: 34442147 DOI: 10.3390/healthcare9081010] [Reference Citation Analysis]
61 Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, Rinaldi L, Salvatore T, Marfella R, Sardu C, Moscarella E, Gragnano F, Calabrò P, Sasso FC. Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. Diabetes Res Clin Pract 2021;178:108959. [PMID: 34280467 DOI: 10.1016/j.diabres.2021.108959] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
62 Nishikawa H, Yoh K, Enomoto H, Nishiguchi S, Iijima H. Dynapenia Rather Than Sarcopenia Is Associated with Metabolic Syndrome in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2021;11:1262. [PMID: 34359344 DOI: 10.3390/diagnostics11071262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
64 Kalra S, Bhattacharya S, Rawal P. Hepatocrinology. Med Sci (Basel) 2021;9:39. [PMID: 34205986 DOI: 10.3390/medsci9020039] [Reference Citation Analysis]
65 Paniz GR, Arroyo-mercado FM, Ling CL, Choi EE, Snow HE, Rakov NE, Castillo EF. Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study.. [DOI: 10.1101/2021.05.27.21257690] [Reference Citation Analysis]
66 Allegra M. Redox Regulation of Metabolic Syndrome: From Biochemical Mechanisms to Nutritional Interventions. Antioxidants (Basel) 2021;10:638. [PMID: 33921926 DOI: 10.3390/antiox10050638] [Reference Citation Analysis]